LGVN

Longeveron
LGVN

$2.06

0.49%

Market Cap: $29.6M

About: Longeveron Inc is a clinical-stage biotechnology company developing regenerative medicines to address unmet medical needs for specific aging-related and life-threatening conditions. Its investigational product is Lomecel-B an stem cell formulation sourced from the bone marrow of young, healthy adult donors and has potential mechanisms of action that can promote tissue repair and healing. The company currently has three pipeline indications: Hypoplastic Left Heart Syndrome (HLHS), Alzheimer's disease (AD) and Aging-related Frailty.

Employees: 24

Healthcare Pharmaceutical Preparations

0

Funds holding %

of 6,710 funds

0

Analysts bullish %

of 5 analysts

Fund manager confidence

Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)

300% more first-time investments, than exits

New positions opened: 12 | Existing positions closed: 3

230% more capital invested

Capital invested by funds: $162K [Q1] → $534K (+$372K) [Q2]

75% more funds holding

Funds holding: 12 [Q1] → 21 (+9) [Q2]

67% more repeat investments, than reductions

Existing positions increased: 5 | Existing positions reduced: 3

1.97% more ownership

Funds ownership: 4.83% [Q1] → 6.8% (+1.97%) [Q2]

See Fund Rankings

Research analyst outlook

5 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target

$6

191%

upside

Avg. target

$9.20

347%

upside

High target

$10

385%

upside

5 analyst ratings

5 positive

100%

0 neutral

0%

0 negative

0%

HC Wainwright & Co. Raghuram Selvaraju 44% 1-year accuracy 121 / 273 met price target	385%upside $10	Buy Reiterated	4 Sept 2024
Maxim Group Michael Okunewitch 75% 1-year accuracy 3 / 4 met price target	191%upside $6	Buy Maintained	27 Aug 2024
HC Wainwright & Co. Raghuram Selvaraju 44% 1-year accuracy 121 / 273 met price target	385%upside $10	Buy Reiterated	15 Aug 2024
HC Wainwright & Co. Raghuram Selvaraju 44% 1-year accuracy 121 / 273 met price target	385%upside $10	Buy Reiterated	31 Jul 2024
HC Wainwright & Co. Raghuram Selvaraju 44% 1-year accuracy 121 / 273 met price target	385%upside $10	Buy Maintained	29 Jul 2024

See Analyst Rankings

Financial journalist opinion

Longeveron to Present at the H.C. Wainwright 26th Annual Global Investment Conference

MIAMI, Aug. 26, 2024 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN), a clinical stage regenerative medicine biotechnology company developing cellular therapies for life-threatening and chronic aging-related conditions, today announced that it will participate in the H.C. Wainwright 26th Annual Global Investment Conference taking place September 9-11, 2024 in New York City.

Longeveron to Present at the H.C. Wainwright 26th Annual Global Investment Conference

Longeveron, Inc. (LGVN) Q2 2024 Earnings Call Transcript

Longeveron, Inc. (NASDAQ:LGVN ) Q2 2024 Earnings Conference Call August 14, 2024 4:30 PM ET Company Participants Derek Cole - IR, Advisory Solutions Wa'el Hashad - CEO Nataliya Agafonova - CMO Lisa Locklear - CFO Joshua Hare - Co-Founder, Chief Science Officer & Chairman Conference Call Participants Ram Selvaraju - H.C. Wainwright Operator Good day, and welcome to Longeveron's 2024 Second Quarter Financial Results Conference Call.

Longeveron, Inc. (LGVN) Q2 2024 Earnings Call Transcript

The Top 3 Small-Cap Stocks to Buy Now: Summer 2024

Small-cap stocks are back in favor. After languishing behind their larger brethren for years, small-cap stocks are roaring ahead as investors rotate into the sector once more.

The Top 3 Small-Cap Stocks to Buy Now: Summer 2024

Longeveron (LGVN) Stock Pops on Phase 2 Trial Updates

Longeveron (NASDAQ: LGVN ) jumped after publishing a press release stating that Phase 2a results for its Alzheimer's treatment met primary endpoints. Lomecel-B is a treatment for mild cases of Alzheimer's disease.

Longeveron (LGVN) Stock Pops on Phase 2 Trial Updates

Longeveron® Presents Study Results from CLEAR MIND Phase 2a Clinical Trial of Lomecel-B™ in Mild Alzheimer's Disease at the Alzheimer's Association International Conference® (AAIC)

Longeveron Phase 2a clinical results in Alzheimer's Disease selected for Featured Research oral presentation at Alzheimer's Association International Conf

Longeveron® Presents Study Results from CLEAR MIND Phase 2a Clinical Trial of Lomecel-B™ in Mild Alzheimer's Disease at the Alzheimer's Association International Conference® (AAIC)

Longeveron Announces Closing of $9.0 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

MIAMI, July 19, 2024 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN) (“Longeveron” or the “Company”), a clinical stage regenerative medicine biotechnology company developing cellular therapies for life-threatening and chronic aging-related conditions, today announced the closing of its previously announced registered direct offering priced at-the-market under Nasdaq rules, for the issuance and sale of an aggregate of 2,236,026 shares of its Class A common stock (or common stock equivalents in lieu thereof) at a purchase price of $4.025 per share of Class A common stock (or per common stock equivalent in lieu thereof) in a registered direct offering priced at-the-market under Nasdaq rules. In a concurrent private placement, the Company issued unregistered warrants to purchase up to an aggregate of 2,236,026 shares of Class A common stock.

Longeveron Announces Closing of $9.0 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Longeveron Announces $9.0 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

MIAMI, July 18, 2024 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN) (“Longeveron” or the “Company”), a clinical stage regenerative medicine biotechnology company developing cellular therapies for life-threatening and chronic aging-related conditions, today announced that it has entered into definitive agreements for the issuance and sale of an aggregate of 2,236,026 shares of its Class A common stock (or common stock equivalents in lieu thereof) at a purchase price of $4.025 per share of Class A common stock (or per common stock equivalent in lieu thereof) in a registered direct offering priced at-the-market under Nasdaq rules. In a concurrent private placement, the Company has also agreed to issue and sell unregistered warrants to purchase up to an aggregate of 2,236,026 shares of Class A common stock.

Longeveron Announces $9.0 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

LGVN Stock Alert: Longeveron Pops 18% on FDA Fast-Track Designation

Longeveron (NASDAQ: LGVN ) stock is rocketing higher on Wednesday after the clinical-stage biotechnology company received fast-track designation for its mild Alzheimer's Disease treatment. This has the Food and Drug Administration (FDA) granting this designation to Lomecel-B.

LGVN Stock Alert: Longeveron Pops 18% on FDA Fast-Track Designation

7 Meme Stocks That Deserve a Fresh Set of Eyes

Meme stocks – you know them as social-media-inspired securities that tend to be speculative. Generally speaking, it's difficult to suggest otherwise.

7 Meme Stocks That Deserve a Fresh Set of Eyes

Longeveron stock opened 100% up on Wednesday: explore why

Longeveron Inc (NASDAQ: LGVN) soared 100% on Wednesday after its Lomecel-B received RMAT designation from the Food & Drug Administration. Lomecel-B is the company's investigational treatment for Alzheimer's disease.

Longeveron stock opened 100% up on Wednesday: explore why

See News Rankings